{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:55:40Z","timestamp":1740135340526,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000291","name":"Kidney Research UK","doi-asserted-by":"publisher","award":["RP39\/2014","RP39\/2014","RP39\/2014"],"award-info":[{"award-number":["RP39\/2014","RP39\/2014","RP39\/2014"]}],"id":[{"id":"10.13039\/501100000291","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["RG\/12\/4\/29426"],"award-info":[{"award-number":["RG\/12\/4\/29426"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>T-type calcium channels (TTCC) are low voltage activated channels that are widely expressed in the heart, smooth muscle and neurons. They are known to impact on cell cycle progression in cancer and smooth muscle cells and more recently, have been implicated in rat and human mesangial cell proliferation. The aim of this study was to investigate the roles of the different isoforms of TTCC in mouse mesangial cells to establish which may be the best therapeutic target for treating mesangioproliferative kidney diseases.\u00a0<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this study, we generated single and double knockout (SKO and DKO) clones of the TTCC isoforms Ca<jats:sub>V<\/jats:sub>3.1 and Ca<jats:sub>V<\/jats:sub>3.2 in mouse mesangial cells using CRISPR-cas9 gene editing. The downstream signals linked to this channel activity were studied by ERK1\/2 phosphorylation assays in serum, PDGF and TGF-\u03b21 stimulated cells. We also examined their proliferative responses in the presence of the TTCC inhibitors mibefradil and TH1177.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We demonstrate a complete loss of ERK1\/2 phosphorylation in response to multiple stimuli (serum, PDGF, TGF-\u03b21) in Ca<jats:sub>V<\/jats:sub>3.1 SKO clone, whereas the Ca<jats:sub>V<\/jats:sub>3.2 SKO clone retained these phospho-ERK1\/2 responses. Stimulated cell proliferation was not profoundly impacted in either SKO clone and both clones remained sensitive to non-selective TTCC blockers, suggesting a role for more than one TTCC isoform in cell cycle progression. Deletion of both the isoforms resulted in cell death.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study confirms that TTCC are expressed in mouse mesangial cells and that they play a role in cell proliferation. Whereas the Ca<jats:sub>V<\/jats:sub>3.1 isoform is required for stimulated phosphorylation of ERK1\/2, the Ca <jats:sub>V<\/jats:sub>3.2 isoform is not. Our data also suggest that neither isoform is necessary for cell proliferation and that the anti-proliferative effects of mibefradil and TH1177 are not isoform-specific. These findings are consistent with data from in vivo rat mesangial proliferation Thy1 models and support the future use of genetic mouse models to test the therapeutic actions of TTCC inhibitors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-022-02844-1","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T14:03:02Z","timestamp":1655388182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stimulated phosphorylation of ERK in mouse kidney mesangial cells is dependent upon expression of Cav3.1"],"prefix":"10.1186","volume":"23","author":[{"given":"Sudha Priya Soundara","family":"Pandi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Shattock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce M.","family":"Hendry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire C.","family":"Sharpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"issue":"2","key":"2844_CR1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s12565-016-0334-1","volume":"92","author":"H Kurihara","year":"2017","unstructured":"Kurihara H, Sakai T. Cell biology of mesangial cells: the third cell that maintains the glomerular capillary. Anat Sci Int. 2017;92(2):173\u201386.","journal-title":"Anat Sci Int"},{"issue":"5","key":"2844_CR2","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/ki.1983.203","volume":"24","author":"R Pabst","year":"1983","unstructured":"Pabst R, Sterzel RB. Cell renewal of glomerular cell types in normal rats. An autoradiographic analysis. Kidney Int. 1983;24(5):626\u201331.","journal-title":"Kidney Int"},{"issue":"5","key":"2844_CR3","first-page":"601","volume":"65","author":"CM Pesce","year":"1991","unstructured":"Pesce CM, Striker LJ, Peten E, Elliot SJ, Striker GE. Glomerulosclerosis at both early and late stages is associated with increased cell turnover in mice transgenic for growth hormone. Lab Invest. 1991;65(5):601\u20135.","journal-title":"Lab Invest"},{"issue":"2","key":"2844_CR4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/ki.1992.42","volume":"41","author":"J Floege","year":"1992","unstructured":"Floege J, Burns MW, Alpers CE, Yoshimura A, Pritzl P, Gordon K, Seifert RA, Bowen-Pope DF, Couser WG, Johnson RJ. Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int. 1992;41(2):297\u2013309.","journal-title":"Kidney Int"},{"issue":"3","key":"2844_CR5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/ki.1991.235","volume":"40","author":"J Floege","year":"1991","unstructured":"Floege J, Johnson RJ, Gordon K, Iida H, Pritzl P, Yoshimura A, Campbell C, Alpers CE, Couser WG. Increased synthesis of extracellular matrix in mesangial proliferative nephritis. Kidney Int. 1991;40(3):477\u201388.","journal-title":"Kidney Int"},{"issue":"2","key":"2844_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.tice.2015.12.007","volume":"48","author":"X Feng","year":"2016","unstructured":"Feng X, Wu C, Yang M, Liu Q, Li H, Liu J, Zhang Y, Hao Y, Kang L, Zhang Y, et al. Role of PI3K\/Akt signal pathway on proliferation of mesangial cell induced by HMGB1. Tissue Cell. 2016;48(2):121\u20135.","journal-title":"Tissue Cell"},{"issue":"4","key":"2844_CR7","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1046\/j.1523-1755.2001.0590041324.x","volume":"59","author":"RE Gilbert","year":"2001","unstructured":"Gilbert RE, Kelly DJ, McKay T, Chadban S, Hill PA, Cooper ME, Atkins RC, Nikolic-Paterson DJ. PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int. 2001;59(4):1324\u201332.","journal-title":"Kidney Int"},{"issue":"4","key":"2844_CR8","first-page":"e74","volume":"108","author":"A Cove-Smith","year":"2008","unstructured":"Cove-Smith A, Hendry BM. The regulation of mesangial cell proliferation. NephronExperimental nephrology. 2008;108(4):e74-79.","journal-title":"NephronExperimental nephrology"},{"issue":"4","key":"2844_CR9","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1046\/j.1523-1755.1999.00710.x","volume":"56","author":"HO Schocklmann","year":"1999","unstructured":"Schocklmann HO, Lang S, Sterzel RB. Regulation of mesangial cell proliferation. Kidney Int. 1999;56(4):1199\u2013207.","journal-title":"Kidney Int"},{"key":"2844_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1242\/jeb.124.1.177","volume":"124","author":"EW McCleskey","year":"1986","unstructured":"McCleskey EW, Fox AP, Feldman D, Tsien RW. Different types of calcium channels. J Exp Biol. 1986;124:177\u201390.","journal-title":"J Exp Biol"},{"issue":"3","key":"2844_CR11","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/ki.1996.120","volume":"49","author":"SR Orth","year":"1996","unstructured":"Orth SR, Nobiling R, Bonisch S, Ritz E. Inhibitory effect of calcium channel blockers on human mesangial cell growth: evidence for actions independent of L-type Ca2+ channels. Kidney Int. 1996;49(3):868\u201379.","journal-title":"Kidney Int"},{"issue":"2","key":"2844_CR12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ajpath.2013.04.029","volume":"183","author":"A Cove-Smith","year":"2013","unstructured":"Cove-Smith A, Mulgrew CJ, Rudyk O, Dutt N, McLatchie LM, Shattock MJ, Hendry BM. Anti-proliferative actions of T-type calcium channel inhibition in Thy1 nephritis. Am J Pathol. 2013;183(2):391\u2013401.","journal-title":"Am J Pathol"},{"issue":"1","key":"2844_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12882-020-01842-5","volume":"21","author":"A Cove-Smith","year":"2020","unstructured":"Cove-Smith A, Sharpe CC, Shattock MJ, Hendry BM. Ion-Channel modulator TH1177 reduces glomerular injury and serum creatinine in chronic mesangial proliferative disease in rats. BMC Nephrol. 2020;21(1):187.","journal-title":"BMC Nephrol"},{"issue":"2","key":"2844_CR14","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1159\/000232590","volume":"113","author":"CJ Mulgrew","year":"2009","unstructured":"Mulgrew CJ, Cove-Smith A, McLatchie LM, Brooks G, Shattock MJ, Hendry BM. Inhibition of human mesangial cell proliferation by targeting T-type calcium channels. Nephron Exp Nephrol. 2009;113(2):e77-88.","journal-title":"Nephron Exp Nephrol"},{"issue":"3","key":"2844_CR15","doi-asserted-by":"publisher","first-page":"C517","DOI":"10.1152\/ajpcell.00107.2010","volume":"300","author":"F Pluteanu","year":"2011","unstructured":"Pluteanu F, Cribbs LL. Regulation and function of Cav3.1 T-type calcium channels in IGF-I-stimulated pulmonary artery smooth muscle cells. Am J Physiol Cell Physiol. 2011;300(3):C517-525.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"2","key":"2844_CR16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00424-017-2068-x","volume":"470","author":"AD Thuesen","year":"2018","unstructured":"Thuesen AD, Andersen K, Lyngso KS, Burton M, Brasch-Andersen C, Vanhoutte PM, Hansen PBL. Deletion of T-type calcium channels Cav3.1 or Cav3.2 attenuates endothelial dysfunction in aging mice. Pflugers Arch. 2018;470(2):355\u201365.","journal-title":"Pflugers Arch"},{"issue":"1","key":"2844_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ceca.2007.03.006","volume":"43","author":"F Lu","year":"2008","unstructured":"Lu F, Chen H, Zhou C, Liu S, Guo M, Chen P, Zhuang H, Xie D, Wu S. T-type Ca2+ channel expression in human esophageal carcinomas: a functional role in proliferation. Cell Calcium. 2008;43(1):49\u201358.","journal-title":"Cell Calcium"},{"issue":"3","key":"2844_CR18","doi-asserted-by":"publisher","first-page":"a008904","DOI":"10.1101\/cshperspect.a008904","volume":"5","author":"RJ Duronio","year":"2013","unstructured":"Duronio RJ, Xiong Y. Signaling pathways that control cell proliferation. Cold Spring Harb Perspect Biol. 2013;5(3):a008904.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"6","key":"2844_CR19","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1097\/01.ASN.0000017576.50319.AC","volume":"13","author":"D Bokemeyer","year":"2002","unstructured":"Bokemeyer D, Panek D, Kramer HJ, Lindemann M, Kitahara M, Boor P, Kerjaschki D, Trzaskos JM, Floege J, Ostendorf T. In vivo identification of the mitogen-activated protein kinase cascade as a central pathogenic pathway in experimental mesangioproliferative glomerulonephritis. J Am Soc Nephrol. 2002;13(6):1473\u201380.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2844_CR20","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1097\/01.ASN.0000057543.55318.8B","volume":"14","author":"HC Clarke","year":"2003","unstructured":"Clarke HC, Kocher HM, Khwaja A, Kloog Y, Cook HT, Hendry BM. Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular cellular proliferation and macrophage number in rat thy-1 nephritis. J Am Soc Nephrol. 2003;14(4):848\u201354.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2844_CR21","first-page":"302","volume":"295","author":"RL Martin","year":"2000","unstructured":"Martin RL, Lee JH, Cribbs LL, Perez-Reyes E, Hanck DA. Mibefradil block of cloned T-type calcium channels. J Pharmacol Exp Ther. 2000;295(1):302\u20138.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"2844_CR22","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1161\/01.HYP.37.5.1268","volume":"37","author":"KA Griffin","year":"2001","unstructured":"Griffin KA, Picken M, Bakris GL, Bidani AK. Comparative effects of selective T- and L-type calcium channel blockers in the remnant kidney model. Hypertension. 2001;37(5):1268\u201372.","journal-title":"Hypertension"},{"issue":"4","key":"2844_CR23","first-page":"1002","volume":"60","author":"DM Haverstick","year":"2000","unstructured":"Haverstick DM, Heady TN, Macdonald TL, Gray LS. Inhibition of human prostate cancer proliferation in vitro and in a mouse model by a compound synthesized to block Ca2+ entry. Cancer Res. 2000;60(4):1002\u20138.","journal-title":"Cancer Res"},{"issue":"2","key":"2844_CR24","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s11095-010-0249-9","volume":"28","author":"CP Landowski","year":"2011","unstructured":"Landowski CP, Bolanz KA, Suzuki Y, Hediger MA. Chemical inhibitors of the calcium entry channel TRPV6. Pharm Res. 2011;28(2):322\u201330.","journal-title":"Pharm Res"},{"issue":"6 Suppl","key":"2844_CR25","doi-asserted-by":"publisher","first-page":"581s","DOI":"10.1378\/chest.128.6_suppl.581S","volume":"128","author":"DM Rodman","year":"2005","unstructured":"Rodman DM, Harral J, Wu S, West J, Hoedt-Miller M, Reese KA, Fagan K. The low-voltage-activated calcium channel CAV3.1 controls proliferation of human pulmonary artery myocytes. Chest. 2005;128(6 Suppl):581s\u20132s.","journal-title":"Chest"},{"issue":"10","key":"2844_CR26","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/j.bbamcr.2017.06.018","volume":"1864","author":"S Sankhe","year":"2017","unstructured":"Sankhe S, Manousakidi S, Antigny F, Arthur Ataam J, Bentebbal S, Ruchon Y, Lecerf F, Sabourin J, Price L, Fadel E, et al. T-type Ca(2+) channels elicit pro-proliferative and anti-apoptotic responses through impaired PP2A\/Akt1 signaling in PASMCs from patients with pulmonary arterial hypertension. Biochim Biophys Acta Mol Cell Res. 2017;1864(10):1631\u201341.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"2844_CR27","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.2147\/CMAR.S172948","volume":"10","author":"S Hu","year":"2018","unstructured":"Hu S, Li L, Huang W, Liu J, Lan G, Yu S, Peng L, Xie X, Yang L, Nian Y, et al. CAV3.1 knockdown suppresses cell proliferation, migration and invasion of prostate cancer cells by inhibiting AKT. Cancer Manag Res. 2018;10:4603\u201314.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"2844_CR28","first-page":"267","volume":"41","author":"T Ohkubo","year":"2012","unstructured":"Ohkubo T, Yamazaki J. T-type voltage-activated calcium channel Cav3.1, but not Cav3.2, is involved in the inhibition of proliferation and apoptosis in MCF-7 human breast cancer cells. Int J Oncol. 2012;41(1):267\u201375.","journal-title":"Int J Oncol"},{"issue":"6","key":"2844_CR29","doi-asserted-by":"publisher","first-page":"C1414","DOI":"10.1152\/ajpcell.00488.2009","volume":"298","author":"A Oguri","year":"2010","unstructured":"Oguri A, Tanaka T, Iida H, Meguro K, Takano H, Oonuma H, Nishimura S, Morita T, Yamasoba T, Nagai R, et al. Involvement of CaV3.1 T-type calcium channels in cell proliferation in mouse preadipocytes. Am J Physiol Cell Physiol. 2010;298(6):C1414-1423.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"6","key":"2844_CR30","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ceca.2004.05.001","volume":"36","author":"LS Gray","year":"2004","unstructured":"Gray LS, Perez-Reyes E, Gomora JC, Haverstick DM, Shattock M, McLatchie L, Harper J, Brooks G, Heady T, Macdonald TL. The role of voltage gated T-type Ca2+ channel isoforms in mediating \u201ccapacitative\u201d Ca2+ entry in cancer cells. Cell Calcium. 2004;36(6):489\u201397.","journal-title":"Cell Calcium"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02844-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-022-02844-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02844-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T14:03:17Z","timestamp":1655388197000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-022-02844-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2844"],"URL":"https:\/\/doi.org\/10.1186\/s12882-022-02844-1","relation":{},"ISSN":["1471-2369"],"issn-type":[{"type":"electronic","value":"1471-2369"}],"subject":[],"published":{"date-parts":[[2022,6,16]]},"assertion":[{"value":"5 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BMH is an employee and stock holder of Travere Therapeutics. CCS has received consulting fees from Novartis Pharmaceuticals, Vifor Pharmaceuticals and Travere therapeutics. MJS and SPSP declare no potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"211"}}